VRAX: SEC Form 6-K filed by Virax Biolabs Group Limited
Stocks in this Quantisnow insightHealth Care
Historical context for VRAX
Across the 5 sessions after earlier VRAX headlines, the stock closed higher 2 times and lower 3 times, with a median move of 11.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | VRAX | SPY |
|---|---|---|---|
| Apr 14, 2026 | Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders | -11.1% | +1.2% |
| Mar 31, 2026 | Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation | +35.3% | +2.9% |
| Dec 5, 2025 | Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement | -2.2% | +0.2% |
| Dec 3, 2025 | Virax Biolabs Group Limited Announces $5 Million Private Placementand 1 other headline that session | +75.1% | +0.3% |
| Nov 3, 2025 | Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes | -3.6% | +0.2% |
Quantisnow market dataNASDAQ
VRAX
Virax Biolabs Group Limited
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Listed since
- 2022
Get push alerts for VRAX
Full VRAX profile on Quantisnow Follow VRAX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time